Thyroid Hormone Therapy and Risk of Thyrotoxicosis in Community-Resident Older Adults: Findings from the Baltimore Longitudinal Study of Aging

Mammen, Jennifer S.; McGready, John; Oxman, Rachael; Chia, Chee W.; Ladenson, Paul W.; Simonsick, Eleanor M.
September 2015
Thyroid;Sep2015, Vol. 25 Issue 9, p979
Academic Journal
Background: Both endogenous and exogenous thyrotoxicosis has been associated with atrial fibrillation and low bone mineral density. Therefore, this study investigated the risk factors associated with prevalent and incident thyrotoxicosis and the initiation of thyroid hormone therapy in a healthy, aging cohort. Methods: A total of 1450 ambulatory community volunteer participants in the Baltimore Longitudinal Study of Aging examined at the NIA Clinical Research Unit in Baltimore, MD, have undergone longitudinal monitoring of serum thyrotropin (TSH) and thyroid hormone (free thyroxine and free triiodothryonine) levels as well as medication use every one to four years, depending on age, between 2003 and 2014. Results: The prevalence of low TSH was 9.6% for participants on thyroid hormone and 0.8% for nontreated individuals ( p < 0.001). New cases occurred at a rate of 17.7/1000 person-years of exposure to thyroid hormone therapy [CI 9-32/1000] and 1.5/1000 person-years in the unexposed population [CI 0.7-2.9/1000]. Women were more likely to be treated and more often overtreated than men were. The adjusted hazard ratio (HR) for thyrotoxicosis between treated and untreated women was 27.5 ([CI 7.2-105.4]; p < 0.001) and 3.8 for men ([CI 1.2-6.3]; p < 0.01). White race/ethnicity and older age were risk factors for thyroid hormone therapy but not overtreatment. Body mass index was not associated with starting therapy (HR = 1.0). Thyroid hormone initiation was highest among women older than 80 years of age (3/100 person-years). For one-third of treated participants with follow-up data, overtreatment persisted at least two years. Conclusions: Iatrogenic thyrotoxicosis accounts for approximately half of both prevalent and incident low TSH events in this community-based cohort, with the highest rates among older women, who are vulnerable to atrial fibrillation and osteoporosis. Physicians should be particularly cautious in treating subclinical hypothyroidism in elderly women in light of recent studies demonstrating no increased risk of cardiovascular morbidity or death for individuals with elevated TSH levels <10 mIU/L.


Related Articles

  • Increased levels of serum angiotensin-converting enzyme activity in hyperthyroidism. Yotsumoto, Hideki; Imai, Yasuo; Kuzuya, Nobuaki; Uchimura, Hidemasa; Matsuzaki, Fukashi; Yotsumoto, H; Imai, Y; Kuzuya, N; Uchimura, H; Matsuzaki, F // Annals of Internal Medicine;Mar1982, Vol. 96 Issue 3, p326 

    Serum angiotensin-converting enzyme activity was significantly elevated in 21 patients with hyperthyroidism (65 +/- 18 U/mL) as compared with levels in healthy control subjects (30 +/- 9 U/mL). In eight patients treated with thionamide drugs, the enzyme activities decreased to a normal range as...

  • Low doses of cholestyramine in the treatment of hyperthyroidism. Mahmoud Kaykhaei; Mesbah Shams; Abdosamad Sadegholvad; Mohammad Dabbaghmanesh; Gholamhossein Omrani // Endocrine (1355008X);Dec2008, Vol. 34 Issue 1-3, p52 

    Abstract  The enterohepatic circulation of thyroid hormones is increased in thyrotoxicosis. Bile-salt sequestrants bind thyroid hormones in the intestine and thereby increase their fecal excretion. Based on these observations, the use of cholestyramine has been tried. The present study...

  • Methimazole.  // AHFS Consumer Medication Information;Dec2019, p1 

    Methimazole is used to treat hyperthyroidism, a condition that occurs when the thyroid gland produces too much thyroid hormone. It is also taken before thyroid surgery or radioactive iodine therapy. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more...

  • Not all elevated hormones are toxic: A case of thyroid hormone resistance. Philip, Rajeev; Padikal, Mohan Krishnakumar; Alinausad, Altaf; Keshavan, Charamelsankaran // Journal of Family Medicine & Primary Care;Apr-Jun2016, Vol. 5 Issue 2, p460 

    Resistance to thyroid hormone syndrome (RTH) is a rare disorder and is usually inherited as dominantly negative autosomal trait. RTH is caused by mutations in the thyroid hormone receptor beta. Patients with RTH usually do not have signs and symptoms of thyrotoxicosis, but the thyroid function...

  • Graves' Disease. MARCUS, SAUL // Naturopathic Doctor News & Review;Aug2014, Vol. 10 Issue 8, p11 

    The article discusses natural treatment options for hyperthyroidism induced by the autoimmune Graves' disease. The risks presented by procedures recommended by endocrinologists such as radioactive uptake scans and iodine treatments and medication with Methimazole are noted. Biotherapeutic...

  • Thyroid Replacement Therapy: The Hidden Challenges. Rahim, Asad; Goundrey-Smith, Stephen // Journal of Endocrinology & Metabolism;2013, Vol. 3 Issue 6, p127 

    Hypothyroidism has a gradual onset and non-specific symptoms, which might be subtle, and which might therefore be ignored or misdiagnosed. Subclinical hypothyroidism is a well-established phenomenon where a patient does not have thyroid symptoms, but shows biochemical evidences of...

  • Propylthiouracil.  // AHFS Consumer Medication Information;Dec2019, p1 

    Propylthiouracil is used to treat hyperthyroidism (a condition that occurs when the thyroid gland produces too much thyroid hormone, speeding the body's metabolism, and causing certain symptoms) in adults and children 6 years of age or older.Propylthiouracil is in a class of medications called...

  • Treatment with thyroid hormone. Gaby, Alan R.; Gaby, A R // JAMA: Journal of the American Medical Association;10/6/89, Vol. 262 Issue 13, p1774 

    Presents a letter to the editor in the October 6, 1989 issue of the 'Journal of the American Medical Association,' noting the advantages of the use of thyroid hormones or thyroid extracts to treat thyrotoxicosis and other diseases.

  • Highlights in thyroidology: a historical vignette. Weissel, Michael // Wiener Klinische Wochenschrift;May2014, Vol. 126 Issue 9/10, p311 

    This review gives a historical overview about the development of today's understanding of benign thyroid diseases and the possibilities of their treatment. Little was known about the thyroid gland until the nineteenth century: the state of knowledge was (1) that something in food, especially in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics